yes- and you were wrong!!
CE is based on safety, manufacturing, quality and performance (rather than efficacy) with weighting to post market data collection. Doubt they’d be going into details of comparative claims, what shrinks a tumour more etc etc - but the market and customer base will. Even Wilson’s say despite CE the evidence base for device is low level. That’s just stating what should be an obvious fact. There are a lot of unanswered questions , the main one being what materially does device really add to outcomes. Nothing sinister in wondering about that . Yeah maybe I should set up zoom call with moksha77, sounds like he/she has picked up several anomalies in this presentation.
Ann: Investor Presentation, page-43
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $23.78M | |||
| Open | High | Low | Value | Volume |
| 0.6¢ | 0.7¢ | 0.6¢ | $116.5K | 16.65M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 12312335 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 3137908 | 9 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| OSL (ASX) Chart |